Adaptive Biotechnologies CORP 8-K filings

Adaptive Biotechnologies announced plans for a $250 million convertible senior notes offering and the separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses.

Adaptive Biotechnologies Corporation shareholders approved director elections, executive compensation advisory vote, and ratified the independent auditor at the June 5, 2026 annual meeting.

Adaptive Biotechnologies announced robust first quarter 2026 financial results, driven by significant growth in its Minimal Residual Disease (MRD) business.

Adaptive Biotechnologies reported robust financial results for Q4 and full year 2025, driven by significant revenue growth and a shift to profitability in its MRD business.

Adaptive Biotechnologies announced preliminary, unaudited Q4 and full year 2025 results, showcasing significant revenue and clonoSEQ test volume increases, and outlining a path to company-wide profitability by late 2026.

Adaptive Biotechnologies' 70% owned subsidiary, Digital Biotechnologies, announced an initial closing of its Series A Preferred Stock financing, targeting up to $15 million.

Adaptive Biotechnologies reported robust third quarter 2025 financial results, driven by significant growth and profitability in its MRD business segment.

Adaptive Biotechnologies Corporation has terminated its 2018 strategic collaboration and license agreement with Genentech, effective February 9, 2026, leading to a $33.7 million non-cash revenue recognition.

Adaptive Biotechnologies reported robust second quarter 2025 financial results, achieving profitability in its MRD business and raising full-year revenue guidance.

Adaptive Biotechnologies Corporation announced that its shareholders approved all three proposals presented at the Annual Meeting held on June 10, 2025, including the election of Chad Robins as a Class III director, the advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor.

Adaptive Biotechnologies announces a strong start to 2025, driven by MRD revenue growth, leading to raised full-year MRD revenue guidance and lowered operating expense and cash burn targets.

Adaptive Biotechnologies reported a 42% growth in MRD revenue for 2024, driven by a 35% increase in clonoSEQ test volume, and is focusing on achieving profitability in MRD and advancing its Immune Medicine pipeline.

Adaptive Biotechnologies saw a 52% increase in MRD revenue and a 30% increase in clonoSEQ test volume in Q3 2024, leading to an improved full-year outlook.

Adaptive Biotechnologies saw a 36% increase in MRD revenue and reduced operating expenses in the second quarter of 2024, despite an overall revenue decrease.

Adaptive Biotechnologies held its annual shareholder meeting, electing two Class II directors, approving executive compensation, and ratifying Ernst & Young as its auditor.

Adaptive Biotechnologies announced an 11% increase in total revenue for Q1 2024, with the MRD business growing by 52% year-over-year, while the Immune Medicine segment saw a 43% decrease.

Adaptive Biotechnologies has appointed Kyle Piskel as its new Chief Financial Officer, effective April 8, 2024, with a base salary of $380,000 and significant equity grants.

Adaptive Biotechnologies will operate its MRD and Immune Medicine businesses internally with dedicated resources, reports preliminary Q1 2024 revenue growth, and announces a CFO transition.

Adaptive Biotechnologies' Chief Financial Officer, Tycho Peterson, has resigned, with Principal Accounting Officer Kyle Piskel set to take over the role.

Adaptive Biotechnologies reported a decrease in overall revenue for both the fourth quarter and full year 2023, despite strong growth in its Minimal Residual Disease (MRD) business, which was offset by a decline in its Immune Medicine (IM) business.